20 May 2013
Keywords: novartis, exelon, cleared, dementia, ad, fda, swiss
Article | 22 May 2006
Swiss drug major Novartis says that its drug candidate Exelon (rivastigmine tartrate) has received a favorable opinion from the
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
22 May 2006
© 2013 thepharmaletter.com